Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Return on Assets (ROA)
since 2005

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Pfizer Inc., ROA, long-term trends, calculation

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions


Net Income
Over the observed period, net income attributable to the company exhibits significant volatility. Initial years show fluctuations between approximately 8,000 million USD and 22,000 million USD, with a notable peak in 2013 at 22,003 million USD. Subsequent years experience both declines and recoveries, peaking again at 31,372 million USD in 2021. However, there is a sharp decrease to 2,119 million USD in 2023, followed by a moderate recovery to 8,031 million USD in 2024. This pattern suggests periodic earnings variability, potentially driven by external factors or one-time items affecting profitability.
Total Assets
Total assets demonstrate an overall increasing trend from 117,565 million USD in 2005 to a peak of 226,501 million USD in 2023. The asset base grows steadily with only minor fluctuations, indicating continued investment and accumulation of resources. There is a slight decline in the last recorded year to 213,396 million USD, which may reflect asset divestitures or adjustments in asset valuations.
Return on Assets (ROA)
ROA displays notable variation, initially ranging between approximately 4% and 17% in the first decade. Peaks occur in 2006 and again in 2018 and 2021, suggesting periods of improved efficiency in generating earnings from assets. A sharp decline is evident in 2023, with ROA dropping to 0.94%, correlating with the significant net income decrease that year. The slight rebound to 3.76% in 2024 follows the partial recovery in net income but remains well below earlier high points. The fluctuations in ROA reflect changes in profitability relative to the asset base.
Summary of Trends
The financial data indicates a company experiencing cycles of profitability with significant peaks and troughs in net income and ROA. Despite these earnings fluctuations, total assets have generally increased, suggesting ongoing asset accumulation or investment. The sharp decline in net income and ROA in 2023 represents a divergence from the otherwise upward trend in assets, indicating possible challenges in income generation efficiency during that period. The partial recovery in 2024 points to stabilization but still at a level below historical highs.

Comparison to Competitors

Pfizer Inc., ROA, long-term trends, comparison to competitors

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)

Pfizer Inc., ROA, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)

Microsoft Excel

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).


Comparison to Industry (Health Care)